<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03358355</url>
  </required_header>
  <id_info>
    <org_study_id>STU00202400</org_study_id>
    <nct_id>NCT03358355</nct_id>
  </id_info>
  <brief_title>Unacylated Ghrelin to Improve FuncTioning in PAD: The GIFT Trial</brief_title>
  <acronym>GIFT</acronym>
  <official_title>Unacylated Ghrelin to Improve FuncTioning in PAD: The GIFT Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The GIFT pilot study will investigate the optimal subcutaneous dose and safety of
      subcutaneously administered unacylated ghrelin in older people with peripheral artery disease
      (PAD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pilot GIFT Trial will obtain preliminary evidence to identify the optimal dose of
      subcutaneously administered unacylated ghrelin in people with PAD. The results of this pilot
      study may be used to design a randomized trial of unacylated ghrelin, in subsequent study, to
      improve functioning and prevent mobility loss in older people with PAD.

      In our primary specific aims, we will 1) establish the association of increasing doses of
      subcutaneous unacylated ghrelin with circulating levels of unacylated ghrelin 2) assess the
      safety of increasing doses of subcutaneously administered unacylated ghrelin in six patients
      with PAD age 55 and older. We will relate peak and Area Under the Curve values of unacylated
      ghrelin to brachial artery flow-mediated dilation (FMD) values. To achieve these aims, six
      PAD participants age 55 and older will receive a single subcutaneous injection of unacylated
      ghrelin at doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg, respectively, on three separate days at
      least one week apart. Unacylated ghrelin levels will be measured at baseline and at defined
      intervals after each subcutaneous injection (30 minutes, 60 minutes, 1.5 hours, 3 hours, 6
      hours, 8 to 12 hours and 24 hours). Brachial artery FMD will be measured at baseline, before
      the unacylated ghrelin injection, approximately six hours, and 24 hours after each unacylated
      ghrelin injection. Blood will be collected and stored for potential later analyses of
      circulating biomarkers, such as inflammatory biomarkers.

      This is a Phase I study to guide dose finding for a pilot study of unacylated ghrelin in
      people with PAD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 7, 2016</start_date>
  <completion_date type="Actual">August 30, 2017</completion_date>
  <primary_completion_date type="Actual">August 30, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Levels of Unacylated Ghrelin</measure>
    <time_frame>Baseline and at scheduled intervals up to 24 hours after baseline</time_frame>
    <description>Levels of unacylated ghrelin are measured before and after every injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brachial Artery Flow-mediated Dilation (FMD)</measure>
    <time_frame>Baseline, 6-8 hours after baseline, 24 hours after baseline.</time_frame>
    <description>Brachial artery flow-mediated dilation in response to hyperemia. The outcome is reporting the MAX Relative FMD 60/90 (%), which is calculated as the highest FMD between the RH60 and RH90 results, as a percent.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants Who Experienced Adverse Events</measure>
    <time_frame>Within 24 hours after subcutaneous injection.</time_frame>
    <description>Adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants Who Experienced Serious Adverse Events</measure>
    <time_frame>Within 24 hours after subcutaneous injection.</time_frame>
    <description>Serious adverse events</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <condition>PAD</condition>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection of unacylated ghrelin: Doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>unacelyated ghrelin</intervention_name>
    <description>We will test doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg of unacylated ghrelin on three separate days for each participant.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. PAD patients age 55 and older

        Exclusion Criteria:

          1. Above or below-knee amputation, critical limb ischemia, and wheelchair confinement.

          2. Cardiovascular event during the previous three months. [Note: Participants who have
             undergone coronary revascularization for a cardiac event during the previous three
             months may still qualify.]

          3. Major medical illnesses including renal disease requiring dialysis, or cancer
             requiring treatment in the previous year.

          4. Participation in another clinical trial or completion of a clinical trial in the
             previous month, unless they were in the control group of the previous trial.

          5. Unwilling to attend nine study visits over approximately six months.

          6. Surgery including lower extremity revascularization or orthopedic surgery in the
             previous month or anticipated surgery in the next three months.

          7. Greater than 15 mmHg difference in blood pressure in both arm pressure measurements
             during the ankle brachial index (ABI), diagnosis of Raynaud's phenomenon, or unable to
             have the blood pressure checked in both arms.

          8. Blood pressure &lt; 90/50 at baseline.

          9. Non-English speaking, a visual impairment that limits ability to read the consent, or
             a hearing impairment that interferes with study participation.

         10. In addition to the above criteria, investigator discretion will be used to determine
             if the trial is unsafe or not a good fit for the potential participant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary McDermott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 19, 2017</study_first_submitted>
  <study_first_submitted_qc>November 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2017</study_first_posted>
  <results_first_submitted>March 28, 2019</results_first_submitted>
  <results_first_submitted_qc>February 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 12, 2020</results_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Mary McDermott</investigator_full_name>
    <investigator_title>Jeremiah Stamler Professor</investigator_title>
  </responsible_party>
  <keyword>PAD</keyword>
  <keyword>unacylated ghrelin</keyword>
  <keyword>Peripheral Artery Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 4, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT03358355/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Unacylated Ghrelin Intervention</title>
          <description>Subcutaneous injection of unacylated ghrelin: Doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg
unacelyated ghrelin: We will test doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg of unacylated ghrelin on three separate days for each participant.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention</title>
          <description>Subcutaneous injection of unacylated ghrelin: Doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg
unacelyated ghrelin: We will test doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg of unacylated ghrelin on three separate days for each participant.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.0" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ankle-Brachial Index (ABI)</title>
          <description>The ABI measures systolic blood pressures in the right brachial, dorsalis pedis, and posterior tibial arteries and left dorsalis pedis, posterior tibial, and brachial arteries. Each measurement is performed twice. The ABI is calculated by dividing mean systolic pressures in each leg by the mean of the 4 brachial pressures.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.69" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.4" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Six-minute walk distance</title>
          <units>feet</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1254.6" spread="531.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Levels of Unacylated Ghrelin</title>
        <description>Levels of unacylated ghrelin are measured before and after every injection</description>
        <time_frame>Baseline and at scheduled intervals up to 24 hours after baseline</time_frame>
        <population>Data originate from participants that received the injection and of which had data available</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention(10 ug/kg)</title>
            <description>Subcutaneous injection of unacylated ghrelin: Doses of 10 ug/kg
unacelyated ghrelin: We will test doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg of unacylated ghrelin on three separate days for each participant.</description>
          </group>
          <group group_id="O2">
            <title>Intervention(20 ug/kg)</title>
            <description>Subcutaneous injection of unacylated ghrelin: Doses of 20 ug/kg
unacelyated ghrelin: We will test doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg of unacylated ghrelin on three separate days for each participant.</description>
          </group>
          <group group_id="O3">
            <title>Intervention(40 ug/kg)</title>
            <description>Subcutaneous injection of unacylated ghrelin: Doses of 40 ug/kg
unacelyated ghrelin: We will test doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg of unacylated ghrelin on three separate days for each participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of Unacylated Ghrelin</title>
          <description>Levels of unacylated ghrelin are measured before and after every injection</description>
          <population>Data originate from participants that received the injection and of which had data available</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>unacylated ghrelin level - Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.34" spread="58.67"/>
                    <measurement group_id="O2" value="58.01" spread="29.98"/>
                    <measurement group_id="O3" value="59.96" spread="31.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unacylated ghrelin level - 30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="845.57" spread="300.12"/>
                    <measurement group_id="O2" value="1522.36" spread="1339.83"/>
                    <measurement group_id="O3" value="1102.99" spread="595.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unacylated ghrelin level - 60 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="772.33" spread="342.00"/>
                    <measurement group_id="O2" value="1719.38" spread="2012.57"/>
                    <measurement group_id="O3" value="1033.50" spread="623.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unacylated ghrelin level - 90 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="763.39" spread="446.80"/>
                    <measurement group_id="O2" value="1998.58" spread="3043.75"/>
                    <measurement group_id="O3" value="982.61" spread="584.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unacylated ghrelin level - 180 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="596.44" spread="371.88"/>
                    <measurement group_id="O2" value="900.83" spread="1078.23"/>
                    <measurement group_id="O3" value="694.51" spread="389.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unacylated ghrelin level - 360 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="373.09" spread="311.77"/>
                    <measurement group_id="O2" value="492.23" spread="489.99"/>
                    <measurement group_id="O3" value="410.49" spread="323.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unacylated ghrelin level - 720 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240.94" spread="135.65"/>
                    <measurement group_id="O2" value="304.62" spread="294.16"/>
                    <measurement group_id="O3" value="339.46" spread="295.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unacylated ghrelin level - 1440 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.29" spread="48.64"/>
                    <measurement group_id="O2" value="57.30" spread="27.34"/>
                    <measurement group_id="O3" value="62.28" spread="34.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brachial Artery Flow-mediated Dilation (FMD)</title>
        <description>Brachial artery flow-mediated dilation in response to hyperemia. The outcome is reporting the MAX Relative FMD 60/90 (%), which is calculated as the highest FMD between the RH60 and RH90 results, as a percent.</description>
        <time_frame>Baseline, 6-8 hours after baseline, 24 hours after baseline.</time_frame>
        <population>Data originate from participants that received the injection and of which had data available</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention(10 ug/kg)</title>
            <description>Subcutaneous injection of unacylated ghrelin: Doses of 10 ug/kg
unacelyated ghrelin: We will test doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg of unacylated ghrelin on three separate days for each participant.</description>
          </group>
          <group group_id="O2">
            <title>Intervention(20 ug/kg)</title>
            <description>Subcutaneous injection of unacylated ghrelin: Doses of 20 ug/kg
unacelyated ghrelin: We will test doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg of unacylated ghrelin on three separate days for each participant.</description>
          </group>
          <group group_id="O3">
            <title>Intervention(40 ug/kg)</title>
            <description>Subcutaneous injection of unacylated ghrelin: Doses of 40 ug/kg
unacelyated ghrelin: We will test doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg of unacylated ghrelin on three separate days for each participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Brachial Artery Flow-mediated Dilation (FMD)</title>
          <description>Brachial artery flow-mediated dilation in response to hyperemia. The outcome is reporting the MAX Relative FMD 60/90 (%), which is calculated as the highest FMD between the RH60 and RH90 results, as a percent.</description>
          <population>Data originate from participants that received the injection and of which had data available</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in FMD 60/90 (%) from baseline to 6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" lower_limit="-0.47" upper_limit="2.21"/>
                    <measurement group_id="O2" value="0.85" lower_limit="0.63" upper_limit="1.17"/>
                    <measurement group_id="O3" value="0.06" lower_limit="-1.56" upper_limit="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in FMD 60/90 (%) from baseline to 24-hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" lower_limit="0.99" upper_limit="1.94"/>
                    <measurement group_id="O2" value="-2.23" lower_limit="-2.70" upper_limit="-2.07"/>
                    <measurement group_id="O3" value="0.11" lower_limit="-0.83" upper_limit="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Who Experienced Adverse Events</title>
        <description>Adverse events</description>
        <time_frame>Within 24 hours after subcutaneous injection.</time_frame>
        <population>Data originate from participants that received the injection and of which had data available</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention(10 ug/kg)</title>
            <description>Subcutaneous injection of unacylated ghrelin: Doses of 10 ug/kg
unacelyated ghrelin: We will test doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg of unacylated ghrelin on three separate days for each participant.</description>
          </group>
          <group group_id="O2">
            <title>Intervention(20 ug/kg)</title>
            <description>Subcutaneous injection of unacylated ghrelin: Doses of 20 ug/kg
unacelyated ghrelin: We will test doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg of unacylated ghrelin on three separate days for each participant.</description>
          </group>
          <group group_id="O3">
            <title>Intervention(40 ug/kg)</title>
            <description>Subcutaneous injection of unacylated ghrelin: Doses of 40 ug/kg
unacelyated ghrelin: We will test doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg of unacylated ghrelin on three separate days for each participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Adverse Events</title>
          <description>Adverse events</description>
          <population>Data originate from participants that received the injection and of which had data available</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>New swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New lightheadedness or dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New headaches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Who Experienced Serious Adverse Events</title>
        <description>Serious adverse events</description>
        <time_frame>Within 24 hours after subcutaneous injection.</time_frame>
        <population>Data originate from participants that received the injection and of which had data available</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Subcutaneous injection of unacylated ghrelin: Doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg
unacelyated ghrelin: We will test doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg of unacylated ghrelin on three separate days for each participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Serious Adverse Events</title>
          <description>Serious adverse events</description>
          <population>Data originate from participants that received the injection and of which had data available</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events will be monitored continuously throughout the study and will be reported to the DSMB and IRB in a timely manner according to pre-specified requirements. We will minimize risk by observing study participants for approximately 8-12 hours after each of the three doses of unacylated ghrelin.</time_frame>
      <desc>Participant that received any injection were monitored for adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Intervention(10 ug/kg)</title>
          <description>Subcutaneous injection of unacylated ghrelin: Doses of 10 ug/kg
unacelyated ghrelin: We will test doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg of unacylated ghrelin on three separate days for each participant.</description>
        </group>
        <group group_id="E2">
          <title>Intervention(20 ug/kg)</title>
          <description>Subcutaneous injection of unacylated ghrelin: Doses of 20 ug/kg
unacelyated ghrelin: We will test doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg of unacylated ghrelin on three separate days for each participant.</description>
        </group>
        <group group_id="E3">
          <title>Intervention(40 ug/kg)</title>
          <description>Subcutaneous injection of unacylated ghrelin: Doses of 40 ug/kg
unacelyated ghrelin: We will test doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg of unacylated ghrelin on three separate days for each participant.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>New swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>New lightheadedness or dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>New headaches</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>New symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mary McDermott MD</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-503-6419</phone>
      <email>mdm608@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

